|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT02148978 |
|
Date of registration:
|
15/05/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Cystic Fibrosis Related Diabetes
|
|
Scientific title:
|
DPP-IV Inhibition in Patients With Cystic Fibrosis |
|
Date of first enrolment:
|
March 2014 |
|
Target sample size:
|
30 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT02148978 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Contacts
|
|
Name:
|
Ram Weiss, MD PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
ramw@ekmd.huji.ac.il |
|
Affiliation:
|
|
|
|
Name:
|
Limor Marko, MSc |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Hebrew University |
|
|
Name:
|
Eitan Kerem, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Hadassah Har Hazofim |
|
|
Name:
|
Karen Hershkop, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Hebrew University |
|
|
Name:
|
Ram Weiss, Professor |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
ramw@ekmd.huji.ac.il |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age > 18 years
- No diabetes based on screening OGTT
- No C/I for use of the medications
- Normal kidney function
- Willing and able to participate
Exclusion Criteria:
- Use of anti-hyperglycemic medications
- Acute illness or infection at enrollment
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Cystic Fibrosis
|
|
Intervention(s)
|
|
Drug: Saxagliptin
|
|
Primary Outcome(s)
|
|
glucose tolerance after treatment with Saxagliptin
[Time Frame: The outcome will be measured at 2 timepoints. at baseline and 6 weeks after Saxagliptin treatment]
|
|
Secondary ID(s)
|
|
0016-14-HMO
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|